Literature DB >> 12597889

Expression, purification, and inhibition of in vitro proteolysis of human AMPD2 (isoform L) recombinant enzymes.

Amy Louise Haas1, Richard L Sabina.   

Abstract

AMP deaminase (AMPD) is a multigene family in higher eukaryotes whose three members encode tetrameric isoforms that catalyze the deamination of AMP to IMP. AMPD polypeptides share conserved C-terminal catalytic domains of approximately 550 amino acids, whereas divergent N-terminal domains of approximately 200-330 amino acids may confer isoform-specific properties to each enzyme. However, AMPD polypeptides are subject to limited N-terminal proteolysis during purification and subsequent storage at 4 degrees C. This presents a technical challenge to studies aimed at determining the structural and functional significance of these divergent sequences. This study describes the recombinant overexpression of three naturally occurring human AMPD2 proteins, 1A/2, 1B/2, and 1B/3, that differ by N-terminal extensions of 47-128 amino acids, resulting from the use of multiple promoters and alternative splicing events. A survey of protease inhibitors reveals that E-64 and leupeptin are able to maintain the subunit structure of each AMPD2 protein when they are included in extraction and storage buffers. Gel filtration chromatography of these three purified AMPD2 enzymes comprised of intact subunits reveals that each migrates faster than expected, resulting in observed molecular masses significantly greater than those predicted for native tetrameric structures. However, chemical crosslinking analysis indicates four subunits per AMPD2 molecule, confirming that these enzymes have a native tetrameric structure. These combined results suggest that AMPD2 N-terminal extensions may exist as extended structures in solution. Copyright 2002 Elsevier Science (USA)

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12597889     DOI: 10.1016/s1046-5928(02)00636-8

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  6 in total

1.  Full-size form of human liver AMP-deaminase?

Authors:  M Szydlowska; Z Chodorowski; I Rybakowska; G Nagel-Starczynowska; K Kaletha
Journal:  Mol Cell Biochem       Date:  2004-11       Impact factor: 3.396

2.  Synthesis and Biochemical Testing of 3-(Carboxyphenylethyl)imidazo[2,1-f][1,2,4]triazines as Inhibitors of AMP Deaminase.

Authors:  Stephen D Lindell; Simon Maechling; Richard L Sabina
Journal:  ACS Med Chem Lett       Date:  2010-06-18       Impact factor: 4.345

3.  AMP-deaminase from normal and cirrhotic human liver: a comparative study.

Authors:  Paweł Dutka; Magdalena Szydłowska; Zygmunt Chodorowski; Iwona Rybakowska; Gabriela Nagel-Starczynowska; Krystian Kaletha
Journal:  Mol Cell Biochem       Date:  2004-07       Impact factor: 3.396

4.  Crystallization and preliminary X-ray crystallographic analysis of adenosine 5'-monophosphate deaminase (AMPD) from Arabidopsis thaliana in complex with coformycin 5'-phosphate.

Authors:  Byung Woo Han; Craig A Bingman; Donna K Mahnke; Richard L Sabina; George N Phillips
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2005-07-08

5.  Isozymes of AMP-Deaminase in Muscles Myasthenia Gravis Patients.

Authors:  Iwona M Rybakowska; Stanisław Bakuła; Krystian Kaletha
Journal:  Int J Pept Res Ther       Date:  2016-05-13       Impact factor: 1.931

Review 6.  Role of the HPRG Component of Striated Muscle AMP Deaminase in the Stability and Cellular Behaviour of the Enzyme.

Authors:  Francesca Ronca; Antonio Raggi
Journal:  Biomolecules       Date:  2018-08-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.